Hevicain Spinal Tung (Bupivacaine Hydrochloride)

Hevicain Spinal Tung is indicated for intrathecal use in a variety of clinical settings where reliable spinal anesthesia is required.

• Induction of surgical anesthesia for procedures below the umbilicus, such as lower abdominal, pelvic, and lower limb surgeries.
• Provision of anesthesia for obstetric procedures, including cesarean delivery, when rapid and dense block is desired.
• Supplementation of general anesthesia to improve postoperative pain control in major surgeries.
• Use in diagnostic or therapeutic spinal procedures, such as lumbar puncture or spinal cord stimulation implantation.
• Management of acute or chronic pain conditions where regional block offers targeted analgesia.

• Bupivacaine hydrochloride, the active component of Hevicain Spinal Tung, is an amide‑type local anesthetic that binds to voltage‑gated sodium channels on neuronal membranes. By stabilizing the inactivated state of these channels, it prevents the influx of sodium ions during depolarization, thereby blocking the generation and propagation of nerve impulses. The resulting inhibition of sensory and motor fibers produces a reversible loss of sensation and muscle tone in the spinal cord region supplied by the injected solution.

Adverse reactions to intrathecal bupivacaine may vary in frequency and severity, ranging from mild, transient symptoms to rare but potentially life‑threatening events that require immediate medical attention.

Common

• Transient hypotension due to sympathetic blockade, often observed shortly after injection.
• Bradycardia or heart‑rate variability, which may be self‑limiting or require intervention.
• Nausea, vomiting, or dizziness, typically mild and manageable with supportive care.
• Pruritus or mild skin flushing, usually transient and resolves without treatment.
• Transient motor weakness or sensory tingling, generally short‑lived.

Serious

• Prolonged high spinal block causing respiratory depression, which may necessitate assisted ventilation.
• Cardiac arrhythmias, including ventricular tachycardia, that can lead to hemodynamic instability.
• Central nervous system toxicity such as seizures, indicating excessive plasma concentrations.
• Persistent neurological deficits.
• Allergic reactions ranging from urticaria to anaphylaxis, requiring prompt identification and treatment.

When using Hevicain Spinal Tung, clinicians should observe several precautions to minimize risks and ensure patient safety.

• Assess cardiovascular status before administration, as patients with severe hypotension or bradycardia may be at increased risk.
• Avoid use in patients with known hypersensitivity to amide‑type local anesthetics.
• Monitor respiratory function continuously, especially after high spinal blocks.
• Maintain resuscitation equipment and emergency drugs readily available during the procedure.
• Consider dose reduction in elderly or frail patients due to altered pharmacodynamics.
• Document and communicate any prior adverse reactions to local anesthetics in the patient’s medical record.

Bupivacaine may interact with other agents, potentially altering its anesthetic effect or increasing toxicity.

Avoid

• Concurrent use of other potent sodium channel blockers (e.g., lidocaine, mexiletine) that may potentiate neurotoxicity.
• High‑dose epinephrine administered intrathecally, which can increase systemic absorption and cardiovascular effects.
• Systemic administration of beta‑blockers or calcium channel blockers that may exacerbate bradycardia.

Use with caution

• General anesthetics such as propofol or volatile agents, which can synergistically depress cardiovascular function.
• Diuretics, because they may affect plasma protein binding and alter free bupivacaine concentrations.
• Anticoagulants, because spinal puncture carries a risk of hematoma in the presence of impaired coagulation.